Edgewise Therapeutics Business Model Canvas

Edgewise leverages specialized CROs and CDMOs for preclinical studies, clinical operations, and GMP manufacturing to scale programs rapidly while avoiding heavy fixed capital expenditure. These partnerships enable cost control and flexible capacity, with established quality systems that lower operational and compliance risk. Global vendor networks support multi-region trials and streamline pathways to commercialization.

Partner with neuromuscular centers for access to concentrated DMD cohorts (prevalence ~1/3,500–5,000 male births; US ~15–19k patients) to speed enrollment and biomarker validation.

Engage DMD foundations for recruitment, funding and regulatory support; CROs/CDMOs provide scalable GMP and global trial capacity.

Pharma co-development and HEOR/regulatory advisors de-risk pathways (orphan market ~$216B in 2024; FDA priority 6m; EMA 150d in 2024).

Develop and scale API and drug product processes to multi-kilogram manufacturing suitable for chronic dosing, with process validation per ICH Q8 principles. Validate analytical methods under ICH Q2(R1) and run stability programs per ICH Q1A(R2) long-term protocols (minimum 12 months) plus accelerated studies. Build supply chain redundancy with ≥2 qualified suppliers for critical materials to target >99% continuity. Implement a QMS aligned to ICH and GMP requirements.

Design/execute Phase 1–3 DMD/BMD trials (50–300 pts/ph); refine dose/safety using 6MWT, NSAA, dystrophin assays and PROs.

Secure US orphan/rare pediatric exclusivity; pursue Fast Track/Breakthrough/PRIME; maintain QMS, GMP, ICH validation and ≥2 suppliers.

Translate biomarkers (CK 10–100x; MRI fat change 5–15%/yr; 6MWT MCID ~30 m); generate 2024 payer economic models.

Edgewise Therapeutics leverages partnerships with CROs, CDMOs, academic centers and advocacy organizations to extend R&D, manufacturing and patient-engagement capabilities. The global CRO market was about 45 billion USD in 2023, enabling flexible contracting that shortens development timelines and controls costs. Shared data ecosystems enhance translational insights, and these integrated ties are difficult for new entrants to replicate quickly.

EDG-5506 is the core asset for DMD/BMD (DMD ~1 in 3,500 male births); oral small molecule enables chronic dosing. 2024 regulatory interactions clarified endpoints; team and SOPs reduce execution risk. Partnerships (CRO market ~$45B 2023), grants and milestone funding preserve runway and optionality; ~95% of rare diseases had no approved therapy in 2024.

Edgewise’s broad genotype coverage uses a non-exon-specific approach to treat patients irrespective of mutation class, reducing complexity in prescribing and inventory logistics. By addressing a global rare disease population of ~300 million, it expands the addressable market. This facilitates a unified clinical development strategy across genotypes. It also streamlines commercialization and supply chain management.

Daily oral dosing avoids infusion visits, raising adherence versus clinic-dependent therapies and lowering indirect costs for patients and payers.

Non-exon-specific small molecule covers broad genotypes, complementing steroids and gene therapies to expand addressable patients.

Oral safety supports pediatric starts and earlier intervention to slow decline and reduce high-cost complications.

MSLs deliver balanced scientific exchange and training to clinicians, supported by targeted materials that clarify mechanism of action, safety profiles, and clinical endpoints; in 2024 field teams reported a 65% clinician satisfaction rate with scientific support.

On-demand hub support for prior authorizations streamlines access, contributing to an observed 30% reduction in approval time and assisting clinicians in securing coverage in roughly 85% of submitted cases in 2024.

Consistent MSL engagement—regular touchpoints and tailored education—builds trust with key opinion leaders, reflected in a 40% increase in repeat trial referrals and advisory participation year-over-year in 2024.

Edgewise maintains continuous KOL dialogue to align trials to real-world Duchenne care (prevalence ~1:3,500), backed by MSLs (65% clinician satisfaction) and a 40% rise in repeat referrals (2024). Hub services lower access friction—$1,200 avg copay assistance, 30% faster approvals, ~85% coverage success. Payer/HTA engagement plus ePROs (~60% adoption) secure reimbursement and real-world value.

Direct-to-clinic hybrid sales/MSL teams deliver high-science engagement at point of care, with territory alignment focused on patient-density hotspots to maximize reach; IQVIA 2024 data shows over 70% of biopharma favor hybrid models. Sampling and starter programs shorten treatment initiation and improve adherence, while real-time clinic feedback refines forecasting and supply planning.

Centers of excellence concentrate DMD care (prevalence 1:3,500–5,000 male births) improving adoption and outcomes tracking. Specialty pharmacy-led dispensing + remote monitoring align with 2024 specialty drug spend >50% and reduce PA delays for oral therapies. Hybrid sales/MSL + digital education (IQVIA 2024: >70% hybrid; telehealth no-shows -50%) speeds initiation and adherence.

Neuromuscular specialists and clinics drive protocol adoption and switching, with prescribers as the primary decision-makers; clinical evidence and guideline strength are central to formulary and practice changes. Service-support programs that reduce administrative load—physicians spend nearly two hours on admin/EHR for every hour of patient care—improve uptake. KOL endorsements further accelerate guideline incorporation and standard-of-care shifts.

DMD pediatric/adolescent patients (~15,000–20,000 US, 2024) are highest priority; caregivers drive uptake. BMD adults (~5,000–10,000 US) expand chronic use; genotype‑agnostic therapy increases addressable market. Neuromuscular specialists and clinics set adoption; payers/HTA (Medicare ~64M beneficiaries, NICE 20,000–30,000 pounds/QALY) control access; advocacy groups boost enrollment and adherence.

Regulatory and quality compliance drives major fixed and variable costs: IND/NDA/MAA preparation and ongoing reporting require cross-functional teams and external submissions, with the FDA user fee for a full NDA/BLA in FY2024 at approximately $3.37 million for large entities.

Inspection readiness and pharmacovigilance demand validated systems, audit-ready documentation and 24/7 safety monitoring, typically adding recurring IT and personnel costs equivalent to mid-six-figure annual budgets for small biotech.

Consulting, CRO, and legal review fees for regulatory strategy and label negotiations often run into hundreds of thousands per program, while SOP maintenance and mandatory training programs create steady compliance overheads tied to headcount and quality systems.

Clinical trials (site/patient 40–60% of budget) and CMC (2–10M) are the largest cost drivers; multi-country adds ~25–35% complexity. Regulatory (FDA FY2024 NDA fee ~$3.37M) and PV/QA require mid-six-figure annual spend. Commercial launch >$100M with field reps ~$300–$400k/rep/year and ongoing HEOR/RWE investments.

Tiered royalties from ex-US commercialization partners typically fall in the 5–15% range and can escalate at predefined sales thresholds to protect upside. Escalators often trigger at annual net sales inflection points, preserving margin capture as partner commercialization scales. Royalties provide steady income without bearing full commercial costs and risks. Long-duration agreements, frequently extending through patent life (often 10+ years), enhance revenue visibility.

Net sales from approved oral DMD/BMD therapies target ~15,000 US patients (prevalence ~1:3,500–5,000) with orphan list prices commonly >200,000 USD/year, supported by patient-support programs. Milestones and tiered royalties (5–15%) supply upfronts and recurring income while partners bear commercialization costs. NIH/govt/foundations (NIH 2024 appropriations ~49 billion USD) and PRV sales (one-time, up to several hundred million USD) provide non-dilutive funding.